975
has not been routine practice to test ABO-incompatible donors for
high-titre anti-A and anti-B. This is unlikely to cause any problem
with platelet transfusions in the form of multiple standard platelet
concentrates, but haemolysis is much more likely with platelet
concentrates prepared by plateletpheresis of a single high-risk
donor. We report a severe haemolytic reaction in a group A1 patient
given a single donor platelet concentrate with high-titre anti-A.
A 30-year-old woman with acute myeloblastic leukaemia was
blood group A1 Rh(D) negative. She achieved a complete remission
after the second of four cycles of chemotherapy. She was
subsequently given cyclophosphamide and total body irradiation
supported by autologous bone-marrow transplantation (ABMT).
Post-ABMT the platelet count did not recover-it remained below
10 000/nl until day 85 and below 20 000/nl until day 115-and she
did not respond to platelet transfusions. She had persistent bleeding
in her mouth and skin and frequent epistaxes. She had multispecific
HLA antibodies, and the responses to platelet transfusions from
unrelated and related HLA-matched and platelet crossmatchcompatible donors were unsatisfactory, and not improved by either
intravenous gammaglobulin (0-4 g/kg for 4 days) or plasma
exchange (5 litres per day for 3 days). She received 58 platelet
transfusions in the first 90 days after ABMT; 48 were single donor
platelet concentrates (volume 200-450 ml) and 25 were from group
0 donors (figure).
On day 72 post-ABMT she felt very unwell after plasma
exchange with 4-5% albumin and a platelet transfusion from a
group 0 HLA-matched donor. On the following morning she was
pale and icteric and her haemoglobin had fallen from 11 4 to
6-0 g/dl; spherocytes were present on the blood film. The direct
antiglobulin test was strongly positive (anti-IgG and C3d) and
anti-A was eluted from her red cells. The donor had an anti-A titre
of 256 by saline agglutination, and 1024 by the indirect antiglobulin
test which was not reduced by treating the serum with
dithiothreitol. The haemolysin test (one volume of a 1 in 4 dilution
of fresh serum from the donor incubated with one volume of a 10%
suspension of test cells) was positive with A1 cells (+++), with A2
cells(+ +),and with B cells ( + ), and negative with 0 cells. Despite
acute renal failure (creatinine clearance 6 ml/min) dialysis was not
required and her renal function returned to normal.
At day 47 post-ABMT there had been a similar episode of
anaemia after a platelet transfusion from the same donor, which had
gone unnoticed. Stored serum from the donor, taken at the time of
the first episode, had an anti-A titre of 512 by saline agglutination
and 2048 by the indirect antiglobulin test. The donor was male and
had no history of transfusion or recent inoculations or infection that
might have boosted his IgG anti-A titre. The greater severity of the
later episode was probably related to the greater volume of plasma
infused (448 ml vs 255 ml).
You recommend that group 0 donors on plateletpheresis panels
should be tested for high titre anti-A and anti-B. However, precise
guidelines have not been set, and there is no generally agreed
discriminatory test. It is most important to avoid transfusing high
titre immune anti-A to an A1 recipient (as in our case). Group A
patients should therefore receive platelets from group A donors
wherever possible, and attention should be given to reducing the
volume of donor plasma in single-donor platelet concentrates.
Department of Haematology,
and ICRF Department of Medical Oncology,
St Bartholomew’s Hospital,
and Medical College,
London EC1A 7BE, UK
M. F. MURPHY
S. HOOK
A. H. WATERS
J. STERLINI
J. WHELAN
C. DAVIS
T. A. LISTER
A, Sintnicolaas K, Claas FHJ, Eernisse JG. ABH antibodies causing platelet
refractoriness. Transfusion 1986; 26: 463-66.
2. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from
ABO-incompatible donors. Transfusion 1985; 25: 60-62.
3. Reis MD, Coovadia AS. Transfusion of ABO-incompatible platelets causing severe
haemolytic reaction. Clin Lab Hæmatol 1989; 11: 237-40.
1. Brand
Lyme borreliosis and Raynaud’s syndrome
SIR,-We believe that some cases of Raynaud’s syndrome1
-usually those that need unpleasant and expensive investigations
and treatment-are caused by Borrelia burgdorferi. These cases
might represent a particular type of Lyme borreliosis. We report
such a case.
In June, 1989—an unusual time for the appearance of Raynaud’s
syndrome-a 38-year-old woman with serious symptoms of
Raynaud’s syndrome was referred to our department. Her disease
had begun suddenly, a short time earlier. Her fingertips were
erythematous and painful. She had two pin-head ulcers on the first
and second fmgers of her left hand. Digital arteries were doppler
positive only after warming her hand in water. All laboratory indices
were normal, apart from the presence of serum antibodies to
Borrelia burgdorferi (titre 3200) detected by the passive
haemagglutination method (PHA; ’Lymag’, Diagast, France). An
absorbent (Diagast) was used to remove cross-reacting antibodies
from the sample before titration. PHA titres above 200 were judged
of diagnostic importance (manufacturer’s recommendation).
976
After 8 weeks’ treatment with doxycycline 300 mg daily,
methisoprinol 3 g daily, and multivitamins, the hand ulcers healed.
Fingertip erythema disappeared and an algid attack could be
provoked only be very cold water or ice. After treatment the serum
antibody titre was 1600. The patient has remained symptom-free
up to December, 1989, and the antibody titre has decreased to 400.
Treatment of Lyme borreliosis is expensive since high doses of
various antibiotics and other drugs are necessary. But our case
suggests that Raynaud’s syndrome caused by Borrelia burgdorferi
also be cured. On the basis of our observations we think it
advisable to look for Lyme borreliosis in Raynaud’s syndrome, even
if there is no indication of such infection and/or the onset of the
disease is unusual.
can
Bajcsy-Zsilinszky Hospital,
Budapest
VERA KRISTÓF
National "Johan Béla’’ Institute of Hygiene,
Budapest H-1966, Hungary
BÉLA P. BÓZSIK
Bajcsy-Zsilinszky Hospital,
Budapest
JÁNOS SIMONYI
MÁRIA SZIRTES
1 Wouda AA, Kallenberg CGM,
Vasa 1987; (suppl 18).
Detection of
Wesseling H, Banga JD. Raynaud’s phenomenon,
serum
hepatitis C virus
RNA
synthesised to contain a BamHI recognition site at its 5’ end. The
primers were used to test for HCV RNA in the sera of six chronic
non-A, non-B hepatitis patients who were positive for HCV
antibody (Ortho Diagnostic Systems enzyme immunoassay). After
one round of amplification, the PCR-amplified sample was
reamplified with a second pair of primers internal to the original pair
(PCR-PCR1).
In all six samples an HCV cDNA band of expected size (176 bp)
was produced on ethidium bromide fluorescence (figure, lanes 1-6).
On the other hand, on PCR-PCR with two successive sets of primer
pairs derived from the Chiron HCV sequence (primers C3751/
C3930R and C3766-E/C3915R-B) none of the six sera was positive
for HCV RNA (figure, lanes 8-13). Another ten sets of primer pairs
from other regions of the Chiron genome also produced
unsatisfactory results.
HCV isolates showed extensive sequence diversity and a PCR
technique based on conserved sequences may revolutionise assays
for detecting HCV RNA and yield valuable information on the
biology of HCV.
First Department of Internal Medicine,
Kanazawa University, Kanazawa 920, Japan
S. KANEKO
M. UNOURA
K. KOBAYASHI
Division of Biophysics,
Cancer Research Institute,
Kanazawa University
K. KUNO
S. MURAKAMI
Tokyo Metropolitan Komagome Hospital
N. HATTORI
SIR,-Dr Weiner and colleagues (Jan 6, p 1) describe the detection
of hepatitis C viral (HCV) sequences in individuals with posttransfusion non-A, non-B hepatitis. However, direct analysis of sera
for HCV genome is still a research tool because the titre of
circulating HCV is usually low, the hybridisation analysis is not
sensitive enough to detect HCV RNA, HCV is very heterogeneous
in respect of its RNA nucleotide sequences, and some HCV
genomes are not detected. We have developed a sensitive procedure
based on the polymerase chain reaction (PCR) technique.
To select efficient and specific primers one HCV cDNA clone,
282 base pair (bp) in size, was isolated from seven samples of liver
from Japanese patients with chronic non-A, non-B hepatitis, and
their sequences were compared with that of the Chiron clone. (The
nucleotide sequences can be obtained from S. K.) The nucleotide
sequences showed 76-77% homology with the Chiron HCV.
However, two sets of primer pair sequences were highly conserved.
Primer JK3779 (5’-GAGTGCGCCTCACACCTTCCTTACATCGAA-3’) begins at map position 3779 of the Chiron HCV
genome; primer JK3966R, from the reverse (R) strand (5’-ATCC-
CGCTGATGAAGTTCCACATGTGCTTC-3’) begins at
position 3966; primer JK3794-E (5’-GACGAATTCCTTCCTTACATCGAACAAGGA-3’) begins at position 3794 and was
synthesised to contain an EcoRI recognition cleavage site at its 5’
end; and primer JK3951R-B (5’-ATGGAATTCTTCCACATGTGCTTCGCCCAG-3’) begins at position 3951 and was
1. Kaneko
S, Feinstone SM, Miller RH Rapid and sensitive method for the detection of
hepatitis B virus DNA using the polymerase chain reaction technique J Clin
serum
Microbiol 1989: 27: 1930-33.
2.
Houghton M, Choo Q-L, Kuo G European patent application no 0318216.
Metronidazole resistance in Helicobacter
pylori
SiR,—Dr Becx and colleagues (March 3, p 539) report
metronidazole resistance in Helicobacter pylori and its association
with previous administration of metronidazole or tinidazole for
unrelated reasons. We have evaluated the frequency of
metronidazole resistance in H pylori isolated from patients differing
in age, race, and geographical setting, and present further data
indicating that resistance is related to earlier nitroimidazole use and
that resistance may vary from population to population. We have
also correlated the rate of resistance in H pylori before treatment
with the clinical efficacy of a nitroimidazole plus amoxycillin
regimen.
H pylori was isolated from 206 unselected patients with H pylori
antral gastritis alone or associated with peptic ulcer disease referred
to our hospitals in Brussels and from 32 black African patients from
rural eastern Zaire. H pylori was cultured from gastric mucosa and
sensitivity to nitroimidazoles before treatment was determined by a
disc diffusion with later retesting by agar dilution with
metronidazole 8 mg/1. Patients with biopsy evidence of gastritis
associated with H pylori were included in open trials of amoxycillin
4 x 500 mg capsules plus tinidazole 2 x 500 mg tablets daily for
7 days. Eradication of H pylori was evaluated by endoscopy with
biopsy and/or a 14C-urea breath test at least 4 weeks after the end of
treatment.
In Brussels the
HCV RNA in
serum
of patients positive for antibody to HCV.
Serum from six patients was analysed for HCV RNA by PCR-PCR RNA
was extracted from 800 J.l1 of serum, cDNA was synthesised with reverse
transcriptase, and amplified by PCR-PCR using two sets of primer
pairs-namely JK3779/JK3966R and JK3794-E/JK3951R-B in lanes
1-6 and primers C3751 /C3930R and C3766-E/C3915R-B in lanes 8-13
A sample from the reaction mixture was subjected to agarose-gel
electrophoresis, and nucleic acid was visualised under ultraviolet light
after staining with ethidium bromide. Lane 7 = molecular weight standard
<t)X174
(HaeIII digest).
rate
of resistance
to
metronidazole
was
27%
(56/206). There was no difference in resistance between males
(29/28) and females (27/109). There was a significant difference in
resistance among native-born Belgians (18/108, 16-6%) compared
with immigrants from Mediterranean countries (Morocco, Greece,
Resistance was more
Turkey, Spain, and Italy) (p<0001).
common in those above age 20 (51/161, 32%) than in younger
patients (6/45, 13%) and was highest in patients aged 30-40 years
(16/27, 59%). However, multivariate analysis revealed that ethnic
origin was the only factor significantly predicting resistance
(p 0-0009); sex and age did not contribute significantly. Of the
children and adolescents investigated in Brussels, 5 out of 6 with
resistant organisms were not Belgian born and could have acquired
=